Blood resin abnormalities are one of the major risk factors for coronary porridge sclerosis. Studies have shown that haemoglobin abnormalities and smoking are two of the strongest risk factors, which together explain two thirds of the risk of heart attack. As the standard of living improves and ageing, the incidence of haematological abnormalities among the Chinese population continues to rise, and the management of blood resin by the general population is imminent. It is particularly important to conduct blood resin management at the grass-roots level. Thus, the Chinese blood resin management guide (2024 basic edition) was issued this year to guide the management of high-lipid haemorrhagic disease in primary hospitals. Awareness and learning about lipid reduction treatment should also be increased among the general population and among persons with high lipid haemorrhagic disorders.
First, low-density protein C is the primary target for blood resin interventions. The target was not a one-size-fits-all, but a different target value based on the hazard layer of coronary porridge sclerosis. First, there is a second and first level of prevention, depending on whether the patient suffers from a coronary porridge. The hazard layer is also based on the number of high-risk factors (e.g. hypertension, diabetes, chronic kidney disease, obesity, smoking, etc.) (please ask your doctor for more details). For low-risk, medium/high-risk, high-risk and ultra-high-risk patients, the target targets for low-density lipoprotein C are 3.4, 2.6, 1.8 (and more than 50 per cent lower than baseline) and 1.4mol/L (and more than 50 per cent lower than baseline).
Clinical classification of haemoglobin abnormalities can generally be classified as hyperglycerine triester haematosis, high cholesterol haemorrhagicemia, mixed hyperlipid haemorrhage, etc. The policy for lipid-reducing treatment is recommended as the initial drug for treatment based on lifestyle interventions, with medium-intensity meds, combined with cholesterol absorbent inhibitors and/or pre-protein conversion enzyme abalone 9 (PCSK9).
A healthy lifestyle is first recommended, including a reasonable diet, a moderate increase in physical activity, weight control, smoking cessation and limited drinking. To put it simply, it means, “Get off your legs and shut up.” It also limits the ingestion of saturated and trans-fatic acid (e.g., cream) and increases the intake of vegetables, fruits, whole grains, food fibres and fish.
Drug treatment is divided into treatment of triesters of high glycerine and treatment of high cholesterol.
Drugs for the reduction of triesters of glycerine consist mainly of beta-type drugs, gill-3 fatty acids, sootic acids and their congeners. However, attention needs to be paid to the side effects of the increase in acute haemoglobin acetic anhydride in the Beta-type. Hetinoids can also reduce triester levels by 7% ~30%. The coronary porridge, which is still very high (2.3 mmol/L) after treatment with beta and tatin-type drugs, poses a high risk to patients above, and can be reduced by a combination of ethyl 20-carbon pentachloroethylene (high-purity pharmaceutical grade fish oil), which further reduces the risk of coronary porridge porridges to hardened heart disease.
The treatment of high cholesterol sepsis can be treated with medium-intensity meds as an initial drug. The use of high-intensity carcasses can have side effects such as absic pain, hepatic enzymes, haematosis, and new diabetes, especially when combined with pressure-relief drugs such as calcium-traffic retardants, the symptoms of the side effects and regular blood checks are observed. The dosage of the drug has doubled, with a 6 per cent increase in lipid reduction. So if cholesterol and low-density lipid protein C do not meet the standard, cholesterol absorbs inhibitors, PCSK9 inhibitors, Probco and other lipids.
The PCSK9 inhibitors currently on the market are Iloyo, Alisiu, Toletsi and RNA Incksland.
Iloyu, against 140 mg or Alisiu, against 75 mg and one per fortnightly subcutaneous, safe and tolerant, will significantly reduce the LDL-C level by ~70%. The incidence of adverse reactions, such as severe adverse events, muscular-related events, new diabetes, hemorrhagic cerebral and neurocognostic events, is similar to that of the placebo group. A similar reduction in low-density protein C can also be obtained from a perforated injection of 150 mg per week or per month. The decrease in density lipoprotein C in Incksland is similar, but it is more persistent, with a dose of a dose of treatment lasting six months. Common adverse effects include pain or swelling, fatigue, nausea and muscle pain in the injection area. Patients can choose according to their type of health insurance and their financial situation.
Hematoma.
